| __timestamp | Ionis Pharmaceuticals, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 17345000000 |
| Thursday, January 1, 2015 | 322292000 | 17404000000 |
| Friday, January 1, 2016 | 344320000 | 17520000000 |
| Sunday, January 1, 2017 | 374644000 | 17175000000 |
| Monday, January 1, 2018 | 1820000 | 18407000000 |
| Tuesday, January 1, 2019 | 4000000 | 14425000000 |
| Wednesday, January 1, 2020 | 12000000 | 15121000000 |
| Friday, January 1, 2021 | 11000000 | 15867000000 |
| Saturday, January 1, 2022 | 14000000 | 15486000000 |
| Sunday, January 1, 2023 | 9133000 | 12472000000 |
| Monday, January 1, 2024 | 12827000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. This analysis compares the cost of revenue for Novartis AG and Ionis Pharmaceuticals, Inc. from 2014 to 2023. Novartis, a Swiss multinational, consistently reported a cost of revenue exceeding $12 billion annually, peaking in 2018. In contrast, Ionis, a smaller biotech firm, saw its highest cost in 2017, with a notable dip in 2018. Over the decade, Novartis's cost of revenue decreased by approximately 28%, while Ionis experienced a more volatile trend, with a 96% drop from its 2017 peak to 2023. This stark contrast highlights the differing scales and operational strategies of these companies. As Novartis streamlines its operations, Ionis's fluctuations may reflect its adaptive strategies in a competitive market. Such insights are invaluable for investors and industry analysts alike.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Johnson & Johnson and Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Novartis AG's Expenses
Analyzing Cost of Revenue: Novartis AG and Xenon Pharmaceuticals Inc.
Analyzing Cost of Revenue: Novartis AG and Mesoblast Limited
Comparing Cost of Revenue Efficiency: Novartis AG vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Novartis AG and Galapagos NV
Cost of Revenue Trends: Sarepta Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Ionis Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Ionis Pharmaceuticals, Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored